Last reviewed · How we verify
Azienda Ospedaliera Universitaria Integrata Verona — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
1 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Tixagevimab Cilgavimab | Tixagevimab Cilgavimab | phase 3 | Monoclonal antibody | SARS-CoV-2 spike protein | Infectious disease |
Therapeutic area mix
- Other · 2
- Infectious disease · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Alexion Pharmaceuticals, Inc. · 1 shared drug class
- Amgen · 1 shared drug class
- Arbeitsgemeinschaft medikamentoese Tumortherapie · 1 shared drug class
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Baxalta now part of Shire · 1 shared drug class
- Bayer · 1 shared drug class
- Biogen · 1 shared drug class
- AgeneBio · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Azienda Ospedaliera Universitaria Integrata Verona:
- Azienda Ospedaliera Universitaria Integrata Verona pipeline updates — RSS
- Azienda Ospedaliera Universitaria Integrata Verona pipeline updates — Atom
- Azienda Ospedaliera Universitaria Integrata Verona pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Azienda Ospedaliera Universitaria Integrata Verona — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/azienda-ospedaliera-universitaria-integrata-verona. Accessed 2026-05-18.